Biogenerics Moving Closer to Commercialization
Biogenerics will have a major impact on the worldwide pharmaceutical marketplace according to Arrowhead Publishers' new report Biogenerics: Challenges and Promise (http://www.arrowheadpublishers.com/Biogenerics.html).
(PRWEB) January 12, 2005 -- The traditional line between research-based
pharmaceutical companies and the growing generics industry is rapidly fading.
More and more companies that straddle that changing boundary are beginning to
understand and appreciate the benefits of a mixed portfolio. As generic
companies begin moving up the value chain to higher priced products, the pharma
giants are increasingly exploring the potential of the fast-growing biogenerics
industry.
Biogenerics: Challenges and Promise, a new report from
Arrowhead Publishers, takes an insightful look at the burgeoning biogenerics
industry.
The report analyzes how the generics industry will be shaped by
the global healthcare market and regulatory developments over the next five
years.
The international biogenerics market faces a multitude of
challenges. Biogenerics: Challenges and Promise will assesses those challenges
and analyzes the potential for maximizing the myriad opportunities available in
this competitive and dynamic industry. The report also appraises and compares
current and emerging biogeneric products and identifies those with the most
potential for growth.
Key questions answered in this report:
•Who
are the major players in the biogenerics arena and what kind of impact are they
making on the industry?
•What obstacles stand in the way of a smooth
transition from biopharmaceutical manufacture to biogenerics?
•How has the
lack of a clear framework impeded the industry’s progress in producing and
distributing biogeneric drugs? And how will these issues be resolved?
•What
specific hurdles must biogeneric manufacturers maneuver in order to get their
products on the market?
This new Arrowhead report
contains:
•Thorough analysis of the drivers of and restraints on the
biogenerics market
•Detailed information and analysis concerning
groundbreaking biogeneric regulation in the US and Europe.
•Identification of
key biopharmaceuticals at risk for biogeneric competition
•In-depth profiles
of leading pharmaceutical companies involved in the biogenerics
industry
•Analytical discussions which integrate regulatory issues with
market activity
and company activity
Contact:
Sales
Department
952-474-5203
www.arrowheadpublishers.com
# # #
Source : http://www.prweb.com/releases/2005/1/prweb194120.htm